| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Cinchoninic acid is an endogenous metabolite and its primary molecular target is not well-defined. It has been shown in preclinical studies to possess anti-cancer activity, particularly against L1210 leukemia and B16 melanoma, suggesting it may interfere with cancer cell proliferation pathways. Its mechanism of action is an area of active investigation, but it may involve the inhibition of specific enzymes or signaling cascades crucial for tumor cell survival.
|
|---|---|
| ln Vitro |
In vitro, Cinchoninic acid has demonstrated anti-tumor activity in cancer cell line models. Studies have shown that it exhibits cytotoxic effects against L1210 leukemia cells and B16 melanoma cells. This suggests that the compound can directly inhibit the growth and proliferation of these cancer cell types in a controlled laboratory setting. The specific IC50 values and detailed mechanisms are part of ongoing pharmacological research.
|
| ln Vivo |
In vivo, Cinchoninic acid has shown anti-tumor efficacy in animal models. As an endogenous metabolite, its presence is a part of normal physiology. However, pharmacological studies have administered the compound to animals to test its therapeutic potential. Results have shown that it possesses anti-tumor activity in models of leukemia and melanoma, indicating that it can slow or prevent tumor growth in a living system.
|
| Enzyme Assay |
The compound can be used in in vitro enzyme assays. It is typically first dissolved in a suitable solvent like DMSO or ethanol to prepare a stock solution. The stock is then diluted to the desired working concentration in an aqueous buffer (e.g., PBS or Tris-HCl). Researchers can use this to test its effect on purified enzymes, measuring activity via spectrophotometric, fluorometric, or other methods to determine if it acts as an inhibitor or modulator.
|
| Cell Assay |
For in vitro cellular experiments, Cinchoninic acid can be added directly to cell culture media. Cancer cell lines, such as L1210 and B16, are seeded in multi-well plates. After allowing them to adhere, the cells are treated with various concentrations of the compound. Following an incubation period (e.g., 24-72 hours), cell viability is measured using standard assays like MTT, CCK-8, or by counting cells to determine its anti-proliferative or cytotoxic effects.
|
| Animal Protocol |
For in vivo animal experiments, such as in a leukemia or melanoma model, the drug is typically administered to rodents. A specific treatment regimen is followed, which could involve intraperitoneal (IP) or intravenous (IV) injections at a defined frequency (e.g., daily or every other day). The animals' tumor growth is monitored over time (e.g., by measuring tumor volume with calipers), and survival rates are recorded to assess the compound's anti-tumor efficacy.
|
| ADME/Pharmacokinetics |
As a preclinical research compound, formal pharmacokinetic (PK) studies for Cinchoninic acid are not widely published. However, as a small aromatic carboxylic acid (MW ~173), it is likely to be absorbed after oral administration, though potentially with low bioavailability due to polarity. It would likely be widely distributed, metabolized via Phase II conjugation (e.g., glucuronidation), and eliminated renally. Its exact PK profile is an area for further investigation.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Cinchoninic acid is not extensively documented in standard safety data sheets for research chemicals. As an endogenous metabolite, it is considered to have low inherent toxicity. However, like many aromatic compounds, it could cause skin, eye, and respiratory tract irritation upon direct contact. Standard laboratory safety precautions, including the use of gloves and safety glasses, are recommended to prevent any adverse effects.
|
| Additional Infomation |
Quinoline-4-carboxylic acid is a quinoline monocarboxylic acid and the conjugate acid of quinoline-4-carboxylate. Quinoline-4-carboxylic acid has been reported in Archangium, with relevant data. See also: Quinoline-4-carboxylate (note moved here).
Cinchoninic acid is not an approved pharmaceutical drug but is a research-use only chemical. It is used as a tool in pharmaceutical development, particularly in oncology research to study cancer cell biology and to screen for potential anti-cancer agents. It also serves as an analytical standard for its detection and quantification in biological samples and as an endogenous metabolite standard in metabolomics studies. |
| Molecular Formula |
C10H7NO2
|
|---|---|
| Molecular Weight |
173.17
|
| Exact Mass |
173.047
|
| CAS # |
486-74-8
|
| PubChem CID |
10243
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
348.7±15.0 °C at 760 mmHg
|
| Melting Point |
254-255 °C(lit.)
|
| Flash Point |
164.7±20.4 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.685
|
| LogP |
1.99
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
205
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=CC=N2)C(=O)O
|
| InChi Key |
VQMSRUREDGBWKT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H7NO2/c12-10(13)8-5-6-11-9-4-2-1-3-7(8)9/h1-6H,(H,12,13)
|
| Chemical Name |
quinoline-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (288.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7747 mL | 28.8734 mL | 57.7467 mL | |
| 5 mM | 1.1549 mL | 5.7747 mL | 11.5493 mL | |
| 10 mM | 0.5775 mL | 2.8873 mL | 5.7747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
